AstraZeneca has signed an agreement with Roche and Qiagen to develop two separate diagnostic tests, both using simple blood samples, to find out patients who will benefit from its lung cancer drugs. At present, the testing of patients to see if their tumors contain genetic mutations that make them suitable for drug treatment involves collecting a sample of tissue by needle biopsy or during surgery. The new tests are based on smart technology ...
via Medindia Health News More READ
No comments:
Post a Comment